Position in DNLI
as of Jun 30, 2026
· filed Jul 22, 2026
Position Value
$5,606
+$5,299 QoQ
Shares Held
218
+1262.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#241
of 290 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SJS Investment Consulting Inc. holds $1,411,656 across 170 Biotechnology names. DNLI ranks #23 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SLS |
SELLAS Life Sciences Group, Inc.
|
40,000 | $590,400 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
840 | $202,414 | |
| 3 | TNXP |
Tonix Pharmaceuticals Holding Corp.
|
10,204 | $130,203 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
877 | $50,181 | |
| 5 | EXEL |
Exelixis, Inc.
|
821 | $44,670 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
59 | $29,306 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
47 | $29,305 | |
| 8 | INCY |
Incyte Corp
|
208 | $23,578 |
All Filings in DNLI
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,606 | 218 | Shares | Defined | 2026-07-22 | |
| 2026-03-31 | $307 | 16 | Shares | Defined | 2026-04-23 | |
| 2025-12-31 | $66 | 4 | Shares | Defined | 2026-01-21 | |
| 2025-09-30 | $58 | 4 | Shares | Defined | 2025-10-21 | |
| 2025-06-30 | $55 | 4 | Shares | Defined | 2025-07-15 | |
| 2025-03-31 | $40 | 3 | Shares | Defined | 2025-04-15 | |
| No filing history on record for this holder in this stock. | ||||||